[Skip to Content]
Upstate Hospital Logo
MENU

Upstate Active Clinical Trials

Study Title:

EAY191-N4: A RANDOMIZED TRIAL OF SELUMETINIB AND OLAPARIB OR SELUMETINIB ALONE IN PATIENTS WITH RECURRENT OR PERSISTENT RAS PATHWAY MUTANT OVARIAN AND ENDOMETRIAL. (ComboMATCH)

What is the purpose of the study? (in Layman's terms, please describe the study)

RAS pathway mutant ovarian and endometrial cancer treated with Selumetinib and Olaparib or Selumetinib alone.

Upstate Institutional Review Board (IRB) Number:

2093576

Study/Protocol ID:

EAY191-N4

Study Phase:

2

Patient Age Group:

Adults

Principal Investigator:

Mary J Cunningham, MD

What is involved if I participate?

  • How long is the study?
    approximately 10 yrs
  • Is transportation provided or reimbursed?
    No
  • Is parking provided or reimbursed?
    No
  • What tests and procedures are involved?
    CMP, CBC w/diff, Beta HCG, EKG, ECHO/MUGA, CT, Bone marrow/blood cytogenetics, tumor biopsy,

Where will the study take place?

Cancer Center or Madison Irving GYN Oncology

Other Information:

N/A

ClinicalTrials.Gov ID:

NCT05554328

For more information about this trial go to ClinicalTrials.Gov

Who can I contact for more information?

Name: Sarah Clark, BS
Phone: 315-464-8276
Email: [email protected]

Return to Previous Page || Search Again

Top